Hypersensitivity reactions to oxaliplatin: what nurses need to know.
Colorectal cancer (CRC) is the third-leading cause of cancer death in the United States. With the advent of new chemotherapy drugs, such as oxaliplatin, for CRC, disease-free and long-term survival has improved in this patient population. As oxaliplatin use increases, more hypersensitivity reactions may be expected. The etiology of these reactions is unclear but may be a combination of immunologic responses. Pretreatment, treatment, and desensitization protocols are available to prevent and treat hypersensitivity reactions. Nurses' rapid assessment and management of infusion-related hypersensitivity reactions are vital to ensuring the safe administration of oxaliplatin.
Bonosky
Kathleen
K
kbonosky@wpahs.org
Miller
Rickey
R
D000970:Antineoplastic Agents / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000451:nursing; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000209:etiology* / Q000451:nursing / Q000628:therapy; D006801:Humans; D009730:Nursing Assessment; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin